Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
ConclusionsTarlatamab–durvalumab maintenance therapy resulted in significantly longer overall survival and progression-free survival than durvalumab alone among patients with extensive-stage small-cell lung cancer.
Appeared: Monday, October 26. New England Journal of Medicine. Peer-reviewed journal.